Evalon

Country: European Union

Language: Romanian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

vaccin împotriva coccidiozei la găini

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI01AN01

INN (International Name):

eimeria acervulina, strain 003, eimeria brunetti, strain 034, eimeria maxima, strain 013, eimeria necatrix, strain 033, eimeria tenella, strain 004

Therapeutic group:

Pui

Therapeutic area:

Live parazitare vaccinuri, produsele imunologice pentru aves

Therapeutic indications:

Pentru imunizarea activă a puilor de 1 zi de varsta pentru a reduce semnele clinice (diaree), leziuni intestinale și oochisturi de ieșire asociate cu coccidioza cauzate de Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix și Eimeria tenella.

Product summary:

Revision: 2

Authorization status:

Autorizat

Authorization date:

2016-04-18

Patient Information leaflet

                                17
B. PROSPECT
18
PROSPECT
EVALON SUSPENSIE ŞI SOLVENT PENTRU PULVERIZARE ORALĂ, PENTRU PUII DE
GĂINĂ.
1.
NUMELE ŞI ADRESA DEŢINĂTORULUI AUTORIZAŢIEI DE COMERCIALIZARE
ŞI A DEŢINĂTORULUI AUTORIZAŢIEI DE FABRICARE, RESPONSABIL PENTRU
ELIBERAREA SERIILOR DE PRODUS, DACĂ SUNT DIFERITE
Deţinătorul autorizaţiei de comercializare şi producătorul
responsabil pentru eliberarea seriei:
Laboratorios Hipra, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
2.
DENUMIREA PRODUSULUI MEDICINAL VETERINAR
Evalon suspensie şi solvent pentru pulverizare orală, pentru puii de
găină.
3.
DECLARAREA (SUBSTANŢEI) SUBSTANŢELOR ACTIVE ŞI A ALTOR
INGREDIENTE (INGREDIENŢI)
Evalon
Substanţe active:
Fiecare doză (0,007 ml) de vaccin nediluat conţine
_Eimeria acervulina, _
tulpina 003 ................................... 332 – 450*
_Eimeria brunetti, _
tulpina 034 ....................................... 213 – 288*
_Eimeria maxima, _
tulpina 013 ....................................... 196 – 265*
_Eimeria necatrix, _
tulpina 033 ....................................... 340 – 460*
_Eimeria tenella, _
tulpina 004 ......................................... 276 – 374*
* Numărul de oochisti sporulati derivati din linii precoce atenuate
de coccidia, conform procedurilor
_in _
_vitro_
ale fabricantului la momentul efectuării amestecului.
HIPRAMUNE T (solvent)
ADJUVANT:
Montanide IMS
EXCIPIENŢI:
Albastru briliant (E133)
Roşu AC (E129)
Vanilină
4.
INDICAŢIE (INDICAŢII)
Pentru imunizarea activă a puilor de găină începând de la vârsta
de o zi, în scopul reducerii semnelor
clinice (diaree), leziunilor intestinale şi formării de oochisturi
în coccidioza cauzată de
_Eimeria _
_acervulina_
,
_Eimeria brunetti,_
_Eimeria maxima,_
_Eimeria necatrix _
şi
_Eimeria tenella_
.
Instalarea imunitatiii: la 3 săptămâni după vaccinare.
Durata imunitatii: 60 de săptămâni după vaccinare, într-un mediu
care permite reciclarea oochistilor.
5.
CONTRAINDICAŢII
Nu există.
19
6.
REACŢII ADVERSE
Nu există.
Dacă
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANEXA I
REZUMATUL CARACTERISTICILOR PRODUSULUI
2
1.
DENUMIREA PRODUSULUI MEDICINAL VETERINAR
Evalon suspensie şi solvent pentru pulverizare orală, pentru puii de
găină.
2.
COMPOZIŢIA CALITATIVĂ ŞI CANTITATIVĂ
Evalon:
Fiecare doză (0,007 ml) de vaccin nediluat conţine:
SUBSTANŢE ACTIVE:
_Eimeria acervulina, _
tulpina 003 ................................... 332 – 450*
_Eimeria brunetti, _
tulpina 034 ....................................... 213 – 288*
_Eimeria maxima, _
tulpina 013 ....................................... 196 – 265*
_Eimeria necatrix, _
tulpina 033 ....................................... 340 – 460*
_Eimeria tenella, _
tulpina 004 ......................................... 276 – 374*
* Numărul de oochisti sporulati derivati din linii precoce atenuate
de coccidia, conform procedurilor
_in _
_vitro_
ale fabricantului la momentul efectuării amestecului.
HIPRAMUNE T (solvent):
ADJUVANT:
Montanide IMS
EXCIPIENŢI:
Albastru briliant (E133)
Roşu AC (E129)
Vanilină
Pentru lista completă a excipienţilor, vezi secţiunea 6.1.
3.
FORMA FARMACEUTICĂ
Suspensie şi solvent pentru pulverizare orală.
Suspensie: Suspensie tulbure de culoare albă.
Solvent: Soluţie de culoare maroniu închis.
4.
PARTICULARITĂŢI CLINICE
4.1
SPECII ŢINTĂ
Pui de găină.
4.2
INDICAŢII PENTRU UTILIZARE, CU SPECIFICAREA SPECIILOR ŢINTĂ

                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-02-2021
Public Assessment Report Public Assessment Report Bulgarian 13-05-2016
Patient Information leaflet Patient Information leaflet Spanish 26-02-2021
Public Assessment Report Public Assessment Report Spanish 13-05-2016
Patient Information leaflet Patient Information leaflet Czech 26-02-2021
Public Assessment Report Public Assessment Report Czech 13-05-2016
Patient Information leaflet Patient Information leaflet Danish 26-02-2021
Public Assessment Report Public Assessment Report Danish 13-05-2016
Patient Information leaflet Patient Information leaflet German 26-02-2021
Public Assessment Report Public Assessment Report German 13-05-2016
Patient Information leaflet Patient Information leaflet Estonian 26-02-2021
Public Assessment Report Public Assessment Report Estonian 13-05-2016
Patient Information leaflet Patient Information leaflet Greek 26-02-2021
Public Assessment Report Public Assessment Report Greek 13-05-2016
Patient Information leaflet Patient Information leaflet English 26-02-2021
Public Assessment Report Public Assessment Report English 13-05-2016
Patient Information leaflet Patient Information leaflet French 26-02-2021
Public Assessment Report Public Assessment Report French 13-05-2016
Patient Information leaflet Patient Information leaflet Italian 26-02-2021
Public Assessment Report Public Assessment Report Italian 13-05-2016
Patient Information leaflet Patient Information leaflet Latvian 26-02-2021
Public Assessment Report Public Assessment Report Latvian 13-05-2016
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2021
Public Assessment Report Public Assessment Report Lithuanian 13-05-2016
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2021
Public Assessment Report Public Assessment Report Hungarian 13-05-2016
Patient Information leaflet Patient Information leaflet Maltese 26-02-2021
Public Assessment Report Public Assessment Report Maltese 13-05-2016
Patient Information leaflet Patient Information leaflet Dutch 26-02-2021
Public Assessment Report Public Assessment Report Dutch 13-05-2016
Patient Information leaflet Patient Information leaflet Polish 26-02-2021
Public Assessment Report Public Assessment Report Polish 13-05-2016
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2021
Public Assessment Report Public Assessment Report Portuguese 13-05-2016
Patient Information leaflet Patient Information leaflet Slovak 26-02-2021
Public Assessment Report Public Assessment Report Slovak 13-05-2016
Patient Information leaflet Patient Information leaflet Slovenian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 26-02-2021
Public Assessment Report Public Assessment Report Slovenian 13-05-2016
Patient Information leaflet Patient Information leaflet Finnish 26-02-2021
Public Assessment Report Public Assessment Report Finnish 13-05-2016
Patient Information leaflet Patient Information leaflet Swedish 26-02-2021
Public Assessment Report Public Assessment Report Swedish 13-05-2016
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2021
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2021
Patient Information leaflet Patient Information leaflet Croatian 26-02-2021
Public Assessment Report Public Assessment Report Croatian 13-05-2016

View documents history